Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of M

Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability is a phase 3, randomised interventional study registered as NCT04804644 by NRG Oncology, with a registry enrolment figure of 152 participants, started 2021-06-08 and due to reach its primary completion in 2026-06-24. Interventions recorded: Biospecimen Collection; Magnetic Resonance Imaging; Memantine Hydrochloride; Neurocognitive Assessment; Stereotactic Radiosurgery; Survey Administration; Whole-Brain Radiotherapy. Conditions listed: Metastatic Lung Small Cell Carcinoma; Metastatic Malignant Neoplasm in the Brain; Recurrent Lung Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8. Primary outcome: Time to neurocognitive failure. Lung eligibility wording from the registry: "* Pathologically (histologically or cytologically) proven diagnosis of small cell lung cancer within 5 years of registration". Sites: Canada, United States. No results are recorded here; the registry entry is the source.